07 June 2021
EMA/319897/2021
EMEA/H/C/000573

Public statement

Nodetrip

Withdrawal of the marketing authorisation in the European Union

On 12 May 2021, the European Commission withdrew the marketing authorisation for Nodetrip (duloxetine) in the EU. The withdrawal was at the request of the marketing authorisation holder, Esteve Pharmaceuticals S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Nodetrip was granted marketing authorisation in the EU on 17 December 2004 for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2009.

The European Public Assessment Report (EPAR) for Nodetrip will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union